Status:
COMPLETED
Minocycline for Schizophrenia
Lead Sponsor:
Addis Ababa University
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Schizophrenia
Eligibility:
All Genders
18-64 years
Phase:
PHASE4
Brief Summary
Schizophrenia is understood to be a heterogeneous brain condition with overlapping symptom dimensions. The negative symptom dimension, with its protean cognitive manifestations, responds poorly to tre...
Detailed Description
Minocycline has excellent penetration of the blood-brain barrier. In a mechanism that seems to be distinct from its antimicrobial properties, minocycline has anti-inflammatory and neuroprotective prop...
Eligibility Criteria
Inclusion
- Age 18-64 years
- Primary Axis I diagnosis (DSM-IV) of schizophrenia, any subtype
- The current episode should be either a relapse episode or a first onset schizophrenia and the duration of the relapse episode and first onset schizophrenia should be under five years
- Indication of treatment-resistance defined by failure of at least on adequate dose of antipsychotic medication (equivalent to chlorpromazine of 200 mg/day or more) given for at least four weeks. For the minority of patients receiving second generation antipsychotic medications, adequate doses will be Risperidone 4mg/day, or Olanzapine 10mg/day.
- Presence of at least moderate symptom severity measured according to the PANSS (score of at least 75)
- On adequate dose of antipsychotic medication at entry and throughout the trial period except during medication switch when participant may take lower doses
- Both genders, but women have to be of non-child bearing age because of potential risks to pregnant women, and the difficulty of ensuring contraception
Exclusion
- Substance abuse co-morbidity or history of substance abuse/dependence within the previous three months
- Impaired cognitive capacity because of a degenerative brain condition or trauma or diagnosis of mental retardation
- Any serious medical condition that affects brain or cognitive function (e.g. epilepsy, serious head injury, brain tumor or other neurological and neurodegenerative conditions)
- Any clinically significant or unstable medical disorder as determined by the investigators that would preclude study participation, including congestive heart failure, abnormal liver function or disease, renal impairment. Also patients with leucopenia, anemia and thrombocytopenia will be excluded.
- History of hypersensitivity to tetracycline
- Patients on anticoagulant therapy
- Patients requiring ergot alkaloids
- Patients taking antacids containing aluminum, calcium or magnesium and iron containing products
- Women of childbearing age (age 18-49 years)
- Increased risk of suicide
Key Trial Info
Start Date :
April 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2016
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01809158
Start Date
April 1 2013
End Date
June 1 2016
Last Update
June 30 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Amanuel Psychiatric Hospital
Addis Ababa, Ethiopia